ABMRF Invests in Amygdala Neurosciences to Develop ANS-858 for Alcohol Use Disorder
Summary
The Foundation was established in 1982 as an independent philanthropic organization dedicated to the development and dissemination of new knowledge about the biological, behavioral and social aspects of alcohol consumption. The US Centers for Disease Control estimated the annual average deaths attributable to excessive alcohol use to be more than 140,000 and the economic cost of AUD to be $249 billion. said Brent Blackburn, PhD, Amygdala co-founder and CEO.ANS-858, a new chemical entity, works in the brains neural interface between motivation and action to reduce the dopamine surge responsible for craving. Preclinical and available clinical data demonstrate the potential of selective, reversible ALDH2 inhibition as a promising target for treatment of AUD. The company was formed based on technology discovered and developed by members of the companies leadership team while at CV Therapeutics and acquired from Gilead Sciences.The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.SOURCE: ABMRF, The Foundation for Alcohol Research, and Amygdala Neurosciences Inc Related Links https://www.abmrf.org/, http://www.amygns.com